A draft guideline from the World Health Organization has shown that it will recommend using weight loss medications to treat obesity in adults, and urges states to take the issue of obesity seriously as a chronic disease.
The WHO Experts Committee concluded that the common GLP-1 drugs, which are drugs that depend on the simulation of the Holocoragon-1 peptide, which was Novo Nordisk and Elie Lily’s first to developed, are part of the solution to treat obesity for patients who have a BMI (BMI) at 30 or more, along with consulting on lifestyle changes and behavior changes.
Reuters first reported in May that the World Health Organization is likely to take this step.
In the draft guidelines published on the Internet and open to consultation until September 27, the World Health Organization stated that the confrontation of the problem of obesity is often formed on the basis of outdated old views that it imagines as a lifestyle problem.
But the organization said instead that the problem of obesity is “a chronic, aggravated and repeated disease” affects more than a billion people around the world in both high and low -income countries and contributes to millions of deaths that could have been avoided.
The organization recommended for the first time the use of these drugs to treat obesity, describing it as an important step to develop a global standard of care. The organization is currently working on separate guidelines for treating children and adolescents.
The WHO’s guidelines apply to those who have a body mass index above only 30, but in some high -income countries such as the United States, these medications are also recommended for those who have a body mass index between 27 and 30 and suffer from at least one medical condition linked to weight.
Earlier this month, the World Health Organization did not reach the extent of adding these drugs to treat obesity to the basic drug list, a separate list that includes medicines that should be available in all operating health care systems.
But it has already added it to type 2 diabetics, the disease that companies have developed these medications originally, if they were combined with another health condition.
The organization added that this indicates patients who will benefit more than these expensive treatments, noting that high prices limit the possibility of obtaining medicines in low and medium -income countries.